HRP20211839T1 - Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima - Google Patents

Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima Download PDF

Info

Publication number
HRP20211839T1
HRP20211839T1 HRP20211839TT HRP20211839T HRP20211839T1 HR P20211839 T1 HRP20211839 T1 HR P20211839T1 HR P20211839T T HRP20211839T T HR P20211839TT HR P20211839 T HRP20211839 T HR P20211839T HR P20211839 T1 HRP20211839 T1 HR P20211839T1
Authority
HR
Croatia
Prior art keywords
group
hydrogen atom
quinolin
trifluoromethoxy
amine
Prior art date
Application number
HRP20211839TT
Other languages
English (en)
Croatian (hr)
Inventor
Jamal Tazi
Florence Mahuteau-Betzer
Romain Najman
Didier Scherrer
Noëlie CAMPOS
Aude Garcel
Original Assignee
Abivax
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Etablissement Public)
Institut Curie
Universite De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abivax, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Etablissement Public), Institut Curie, Universite De Montpellier filed Critical Abivax
Publication of HRP20211839T1 publication Critical patent/HRP20211839T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20211839TT 2013-07-05 2014-07-04 Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima HRP20211839T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843155P 2013-07-05 2013-07-05
EP14758168.0A EP3016656B1 (en) 2013-07-05 2014-07-04 Bicyclic compounds useful for treating diseases caused by retroviruses
PCT/IB2014/062849 WO2015001518A1 (en) 2013-07-05 2014-07-04 Bicyclic compounds useful for treating diseases caused by retroviruses

Publications (1)

Publication Number Publication Date
HRP20211839T1 true HRP20211839T1 (hr) 2022-03-04

Family

ID=51453778

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211839TT HRP20211839T1 (hr) 2013-07-05 2014-07-04 Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima

Country Status (16)

Country Link
US (1) US9827237B2 (https=)
EP (1) EP3016656B1 (https=)
JP (2) JP6895251B2 (https=)
KR (1) KR102326068B1 (https=)
CN (1) CN105530938B (https=)
AU (1) AU2014285733B2 (https=)
BR (1) BR112016000127B1 (https=)
CA (1) CA2916623C (https=)
ES (1) ES2898385T3 (https=)
HR (1) HRP20211839T1 (https=)
MX (1) MX382692B (https=)
PL (1) PL3016656T3 (https=)
PT (1) PT3016656T (https=)
RU (1) RU2681943C9 (https=)
WO (1) WO2015001518A1 (https=)
ZA (1) ZA201600317B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059591A1 (en) * 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
EP3059236A1 (en) 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
KR20170109160A (ko) 2016-03-18 2017-09-28 현대자동차주식회사 엔진마운트의 체결구조
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
EP3848356A1 (en) * 2020-01-07 2021-07-14 Abivax Aryl-n-aryl derivatives for treating a rna virus infection
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk﹘5抑制劑和彼之用途
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US20240327388A1 (en) 2021-05-27 2024-10-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物
CN116120282B (zh) * 2022-08-04 2024-02-20 苏州系统医学研究所 具有ev71和/或cva16病毒抑制活性的化合物及其应用
EP4624469A4 (en) 2022-11-25 2026-04-15 Jiangsu Hengrui Pharmaceuticals Co Ltd CRYSTALLINE FORM OF QUINOLEIN AMINE COMPOUND AND ITS PREPARATION PROCESS
CN118373771A (zh) 2023-01-20 2024-07-23 江苏柯菲平医药股份有限公司 一种喹啉衍生化合物或其可药用的盐及其制备方法和应用
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating microRNA activity A-124

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB585362A (en) 1944-08-31 1947-02-05 Francis Henry Swinden Curd New heterocyclic compounds
BE486034A (https=) 1947-11-28
DE958647C (de) 1952-12-28 1957-02-21 Hoechst Ag Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen
FR2387229A1 (fr) 1977-04-13 1978-11-10 Anvar Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
FR2436786A1 (fr) 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
FR2627493B1 (fr) 1988-02-23 1991-10-31 Sanofi Sa Procede de preparation de derives d'isoquinoleine
FR2645861A1 (fr) 1989-04-17 1990-10-19 Inst Nat Sante Rech Med Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
WO2000059875A2 (en) 1999-04-05 2000-10-12 City Of Hope Novel inhibitors of formation of advanced glycation endproducts (age's)
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2006081444A2 (en) 2005-01-28 2006-08-03 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
FR2849474B3 (fr) 2002-12-27 2004-12-03 Olivier Jean Noel Juin Installation de transformation de l'energie cinetique d'un fluide en energie electrique
WO2004078731A1 (en) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Quinoline-carboxylic acids and the derivatives thereof, a focused library
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
FR2859475A1 (fr) 2003-09-04 2005-03-11 Centre Nat Rech Scient Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
FR2912745A1 (fr) 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20100249184A1 (en) 2007-03-16 2010-09-30 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
US8222634B2 (en) 2007-05-17 2012-07-17 Lg Chem, Ltd. Anthracene derivatives and organic electronic device using the same
AU2008286760A1 (en) 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
WO2009029617A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
EP2266972A1 (en) * 2009-06-12 2010-12-29 Splicos New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
SI2440547T1 (sl) * 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
US8962583B2 (en) 2009-06-25 2015-02-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory diseases using miR-124
EP2465502A1 (en) 2010-12-15 2012-06-20 Société Splicos Compounds useful for treating AIDS
JP2016504268A (ja) * 2012-10-04 2016-02-12 オヤジェン インコーポレイテッドOyaGen, Inc. Vifの自己会合を撹乱する抗hiv剤としての小分子及びその使用方法
EP2757161A1 (en) * 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection

Also Published As

Publication number Publication date
KR102326068B1 (ko) 2021-11-11
CN105530938A (zh) 2016-04-27
ZA201600317B (en) 2018-07-25
AU2014285733B2 (en) 2019-05-16
WO2015001518A1 (en) 2015-01-08
MX2015017599A (es) 2016-04-07
RU2681943C2 (ru) 2019-03-14
EP3016656B1 (en) 2021-09-08
BR112016000127A8 (pt) 2018-01-23
CN105530938B (zh) 2019-10-22
JP2016523893A (ja) 2016-08-12
PL3016656T3 (pl) 2022-02-21
JP6895251B2 (ja) 2021-06-30
KR20160032724A (ko) 2016-03-24
BR112016000127B1 (pt) 2022-02-15
MX382692B (es) 2025-03-13
US9827237B2 (en) 2017-11-28
HK1217447A1 (zh) 2017-01-13
RU2681943C9 (ru) 2019-05-16
US20160151348A1 (en) 2016-06-02
EP3016656A1 (en) 2016-05-11
CA2916623A1 (en) 2015-01-08
RU2016103217A (ru) 2017-08-10
CA2916623C (en) 2021-09-14
ES2898385T3 (es) 2022-03-07
AU2014285733A1 (en) 2016-01-21
PT3016656T (pt) 2021-11-26
JP2019142946A (ja) 2019-08-29

Similar Documents

Publication Publication Date Title
HRP20211839T1 (hr) Biciklički spojevi korisni za liječenje bolesti uzrokovanih retrovirusima
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MY204171A (en) Novel sulfonamide carboxamide compounds
GEAP202416435A (en) Anti-viral compounds
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
ME00558A (en) Pyrazole derivatives for treating hiv
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX384729B (es) Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
EA202192512A1 (ru) Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
DE602006020152D1 (de) Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
JOP20230207A1 (ar) مشتقات 2، 4-داي أمينو كوينازولين والاستخدامات الطبية لها
AR109714A1 (es) Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso
MY195177A (en) Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof
MX2020007521A (es) Inhibidores de pi4kiii.
MD3347349T2 (ro) Derivați de fluoroindol ca modulatori alosterici pozitivi ai receptorilor muscarinici M1
EA201800388A1 (ru) Макрогетероциклические нуклеозидные производные и их аналоги, получение и применение
MX2020008982A (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.